Bioventix (BVXP) - Total Liabilities
Based on the latest financial reports, Bioventix (BVXP) has total liabilities worth GBX1.99 Million GBX (≈ $242.48 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioventix - Total Liabilities Trend (2006–2025)
This chart illustrates how Bioventix's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Bioventix's working capital to evaluate short-term liquidity relative to the company's equity base.
Bioventix Competitors by Total Liabilities
The table below lists competitors of Bioventix ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Strix Group Plc
LSE:KETL
|
UK | GBX131.53 Million |
|
Octopus Aim Vct Plc
LSE:OOA
|
UK | GBX683.00K |
|
MultiMetaVerse Holdings Limited
NASDAQ:MMV
|
USA | $35.87 Million |
|
Metavisio (Thomson Computing)
PA:ALTHO
|
France | €40.75 Million |
|
Stelmine Canada Ltd
V:STH
|
Canada | CA$616.27K |
|
Rover Metals Corp
V:ROVR
|
Canada | CA$992.88K |
|
Record PLC
LSE:REC
|
UK | GBX13.32 Million |
|
Spectra Systems Corp
LSE:SPSY
|
UK | GBX22.73 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Bioventix's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Bioventix.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioventix's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioventix (2006–2025)
The table below shows the annual total liabilities of Bioventix from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | GBX1.31 Million ≈ $159.64 |
-24.08% |
| 2024-06-30 | GBX1.73 Million ≈ $210.28 |
+41.90% |
| 2023-06-30 | GBX1.22 Million ≈ $148.19 |
-6.06% |
| 2022-06-30 | GBX1.30 Million ≈ $157.74 |
+19.28% |
| 2021-06-30 | GBX1.09 Million ≈ $132.24 |
+39.54% |
| 2020-06-30 | GBX778.87K ≈ $94.77 |
-1.09% |
| 2019-06-30 | GBX787.43K ≈ $95.81 |
-8.93% |
| 2018-06-30 | GBX864.66K ≈ $105.20 |
+266.29% |
| 2017-06-30 | GBX236.06K ≈ $28.72 |
-58.43% |
| 2016-06-30 | GBX567.86K ≈ $69.09 |
+78.66% |
| 2015-06-30 | GBX317.84K ≈ $38.67 |
-40.13% |
| 2014-06-30 | GBX530.91K ≈ $64.60 |
+72.75% |
| 2013-06-30 | GBX307.34K ≈ $37.39 |
+43.92% |
| 2012-06-30 | GBX213.54K ≈ $25.98 |
+12.03% |
| 2011-06-30 | GBX190.62K ≈ $23.19 |
+5.32% |
| 2010-06-30 | GBX181.00K ≈ $22.02 |
-88.15% |
| 2009-06-30 | GBX1.53 Million ≈ $185.91 |
+27.97% |
| 2008-06-30 | GBX1.19 Million ≈ $145.28 |
+7.86% |
| 2007-06-30 | GBX1.11 Million ≈ $134.69 |
+0.82% |
| 2006-06-30 | GBX1.10 Million ≈ $133.59 |
-- |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more